PLoS One
Department of Neurology, National Neuroscience Institute, Singapore.
Published: December 2011
Background: The relationship between a number of primary sleep disorders and Parkinson's disease (PD) is still debated. There are limited case control polysomnographic studies in PD and most of these study sample sizes are small.
Methodology/findings: We conducted one of the largest case-control studies involving overnight polysomnographic evaluation, with prospective recruitment of unselected Parkinson's disease patients and healthy controls from an Asian population. The cases were recruited from the specialized movement disorder outpatient clinics in a tertiary referral center, and controls from the same geographical locations. All subjects underwent an overnight polysomnographic study and a multiple sleep latency test. A total of 124 subjects including 56 patients and 68 controls frequency-matched for age and sex were included. Multivariate analysis revealed that patients had significantly shorter total sleep time than controls (p = 0.01), lower sleep efficiency (p = 0.001) and increased REM latency (p = 0.007). In patients, multivariate analysis showed that reduced total sleep time was significantly associated with increased age (p = 0.001) and increased levodopa dose (p = 0.032). The mean Insomnia Severity Index was higher in PD patients (9.0±7.1) compared to controls (3.3±3.9, p<0.001). The mean Epworth Sleepiness Scale score was higher in PD patients (9.3±5.9 vs. 5.7±4.8, p<0.001). Nocturnal arousals, obstructive sleep apnea, periodic leg movements and objective abnormal sleepiness were not increased in our patients.
Conclusions/significance: Our case-control polysomnographic study, the first-ever performed in an Asian population, revealed altered sleep architecture and reduced sleep in PD patients compared to controls. Reduced total sleep time was associated with increased age and levodopa dose. However, nocturnal arousals, primary sleep disorders and abnormal sleepiness were not increased in our PD patients suggesting that ethnic/genetic differences may be a factor in the pathophysiology of these conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142152 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022511 | PLOS |
Biol Psychiatry
April 2025
Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, Saint Louis, Missouri; Brain Immunology and Glia Center, Washington University School of Medicine in Saint Louis, Saint Louis, Missouri. Electronic address:
Drug Discov Today
March 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India; Sunway Biofunctional Molecules Discovery Centre (SBMDC), School of Medical and Life Sciences, Sunway University, Sunway, Malaysia. Electronic address:
Over the past decade, dissolving microneedles (DMNs) have emerged as a promising approach for drug delivery to the brain. They are tiny devices designed to penetrate biological barriers, offering a painless method for localized and controlled drug delivery. They are suitable for delivering drugs that are susceptible to degradation when delivered orally.
View Article and Find Full Text PDFBrain Res Bull
March 2025
Kenai Therapeutics, San Diego, CA; Georgetown University Medical Center, Washington, Washington DC.
Intracerebral grafting of dopamine-producing cells is proposed as a strategy to replace the typical neurons lost to Parkinson's disease (PD) and improve the typical PD motor symptoms. Non-human primate studies have provided clues on the relationship between host's immune response and grafting success. Herein, we discuss how the host's immune system differentially affects the graft depending on the origin of the cells and reflect on the advantages and limitations of the immune paradigms utilized to assess graft-related outcomes.
View Article and Find Full Text PDFIEEE Trans Med Imaging
March 2025
Deep learning models have been widely investigated for computing and analyzing brain images across various downstream tasks such as disease diagnosis and age regression. Most existing models are tailored for specific tasks and diseases, posing a challenge in developing a foundation model for diverse tasks. This paper proposes a Dense Transformer Foundation Model with Mixture of Experts (DenseFormer-MoE), which integrates dense convolutional network, Vision Transformer and Mixture of Experts (MoE) to progressively learn and consolidate local and global features from T1-weighted magnetic resonance images (sMRI) for multiple tasks including diagnosing multiple brain diseases and predicting brain age.
View Article and Find Full Text PDFGeroscience
March 2025
Laboratory Genetic Metabolic Diseases, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
Aging is a major risk factor for disease, and developing effective pharmaceutical interventions to improve healthspan and promote longevity has become a high priority for society. One of the molecular pathways related to longevity in various model organisms revolves around lowering AKT1 levels. This prompted our in silico drug screen for small molecules capable of mimicking the transcriptional effects of AKT1 knockdown.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.